ERSP on CigArrest
This article was originally published in The Tan Sheet
Executive Summary
CigArrest, marketer of the eponymous smoking cessation program, has adequately supported its general performance and safety claims, but should modify or discontinue its claim that users can "become a non-smoker in as little as seven days," according to an Electronic Retailing Self-Regulation Program decision Feb. 24. ERSP reviewed a TV ad and website promoting the product and expressed concern about claims such as: "clinically proven methods to help you avoid smoking in any situation" and "the most successful stop smoking program." However, the National Advertising Review Council division found that ingredient claims such as "the active ingredients work...by relieving nervous tension, irritability and the craving associated with withdrawal" were given "adequate" support by scientific literature. Additionally, safety claims including "all-natural, non-addictive" and "we have not had any serious reactions or adverse side-effects ever reported" were reasonably supported by the marketer, ERSP states. CigArrest is a homeopathic formula that includes Nux Vomica (poison nut) and Plantago Major (plantain), the marketer states...
You may also be interested in...
ERSP Review Of Claims Lights Fire Under Smoking-Cessation Marketer
Final Smoke Inc. voluntarily modifies claims for its smoking-cessation system, including a dietary supplement and homeopathic detoxification liquid, in conjunction with an Electronic Retailing Self-Regulation Program review
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.